Sarepta Therapeutics, Inc. (SRPT) saw its loss widen to $88.45 million, or $1.62 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $64.68 million, or $1.44 a share. On the other hand, adjusted net loss for the quarter narrowed to $38.66 million, or $0.71 a share from a loss of $58.33 million or $1.30 a share, a year ago.
Revenue during the quarter surged 332.64 percent to $5.42 million from $1.25 million in the previous year period.
Operating loss for the quarter was $88.40 million, compared with an operating loss of $64.45 million in the previous year period.
"2016 was a transformative year, with the FDA accelerated approval of EXONDYS 51. In 2017, we are focused on our strategy to build shareholder value by executing a successful launch of EXONDYS 51 in the US, reaching more patients through global expansion, and rapidly advancing our pipeline through internal and external development efforts," said Edward Kaye, Sarepta's chief executive officer. "We are pleased with the interest from the patient and physician community for EXONDYS 51, and with the progress we have made in discussions with payers. We believe this positions us well for potential growth and towards our goal at Sarepta Therapeutics to help all boys with Duchenne muscular dystrophy."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
